Skip Navigation
News and Publications
 
 
 
In This Section      
Print This Page

Conquest - Research into Results Timeline

Making the Connection 2001-2008

Research into Results Timeline

Date: April 20, 2010


2001
HPV definitively linked to
certain head and neck cancers.

Cigarette smoke exposure
facility constructed to identify
biomarkers of smoking-induced
cancers.

Baltimore City Public Health
grant for cancer prevention,
education, screening, and
treatment launched.

2002
Clinical studies of a HPV vaccine
to prevent cervical cancer.

Precise calculations made of the
effect of cigarette smoke and
secondhand smoke on cancer.

Lung cancer biomarker
detected in sputum.

A new early detection technique,
ductal lavage, studied
for early detection of breast
cancer.

DNA from 900 volunteers
helps identify biomarkers
of oral cancers.

IGF2 gene identified as a
marker for colon cancer.

Work with an 800,000-member,
racially-diverse labor union
helps pinpoint behaviors linked
to breast, lung, colon, and
prostate cancers.

Partnership with local Korean
churches begins to educate
and screen Korean-American
women for breast and cervical
cancers.

New small-molecule drug
development targets prostate,
breast, and colon cancers.

2003
Model for identification of
carcinogens in food, dust, soil,
and air developed.

Partnerships with faith-based
institutions in Baltimore City
improve cancer education and
screening.

Microarray Core for biomarker
discovered constructed.

Preventive and therapeutic cervical
cancer vaccine development
begins.

Marker for chronic inflammation
used for colon cancer risk
assessment.

Risk-prediction algorithms augment
colon cancer gene testing.

Association between smoking
and colon cancer studied.

Spatial epidemiology used to
quantify geographical variations
in colon cancer incidence and
pinpoint Maryland communities
with environmental risks.

Drugs that block the
negative impact of smoke
on cells are studied.

Nrf2 gene found to alter lungs’
response to cigarette smoke.

Hypermethylation is identified
as an epigenetic marker of lung
cancer.

Influences of smoking cessation
studied in girls 12-16.

Researchers disprove association
between SV40 exposure
through polio vaccines and
mesothelioma development.

Antiangiogenesis drugs studied
as a way to hold tumors in
check.

Combined approaches of
cancer vaccines, chemotherapy
and/or radiation therapy used
to manage treatment resistance.

Computerized technology
helps identify cancer biomarkers
and cancer-gene differences
among races.

Imaging technology used to
monitor drug delivery response.

2004
Molecular on/off switches
engineered to change course
of cancer cells.

Landmark study begins to
uncover causes of high cervical
cancer rates among Maryland’s
African-American women.

Internet, school-based
counseling used in adolescent
smoking cessation programs.

Lung cancer therapeutics
program launched.

Clinical trials of therapeutic
cervical cancer vaccine begin.

Vehicle traffic in urban areas
linked to concentrations of
carcinogens in certain Maryland
communities.

HELP (Hopkins Early Lung
Cancer Prevention Program)
begins.

Drugs that block tyrosine
kinases, cancer cell accelerators,
are studied for their ability to
slow cancer growth.

Arsenic-laced chicken manure
found to be contaminating
Maryland’s Eastern Shore
ground water.

A molecular magnet called
LigAmp pinpoints DNA
mutations among thousands
of cells and make it possible to
detect microscopic cancer.

2005
A novel approach called GINI
identifies gene mutations linked
to prostate cancer.

Smoking cessation methods in
African-American men 18-24
are studied.

Cost effectiveness and success of
cancer control interventions and
strategies evaluated.

Nrf2 is target of lung cancer
chemoprevention trials.

Microarray technology used to
uncover genetic changes in newborns
caused by carcinogen
exposure through drinking water.

Discoveries about the DNA repair
process makes cancer cells more
susceptible to radiation therapy.

Exposure to secondhand
smoke found to increase
risk of cervical cancer.

Statin-takers found to cut risk of
advanced prostate cancer by half.
Broccoli tea chemoprevention
studies in breast, lung, prostate,
and liver cancers begin.

Free nicotine patches distributed
in a joint smoking-cessation study
between Johns Hopkins and the
Washington County Health
Department.

Anti-inflammatory agents and
dietary changes used in prostate
cancer prevention studies.

GSTP1 gene found to protect
cells from cigarette smoke.

Drug atrasentan slows progression
and eases pain of prostate cancer.

2006
Genetic blueprint for breast
and colon cancer revealed.

Kimmel Cancer Center called
research powerhouse with five
Center researchers named best
in the field by Thomas Scientific.

The investigators are the most
frequently cited cancer researchers.

SNP technology developed to
rapidly pinpoint differences in
the coding sequences of genes.

Johns Hopkins Particulate
Matter Research Group developed
to study cancer risks of particulate
matter air pollution.

New therapy targets SRC gene
in pancreatic cancer in an effort
to extend survival.

Blocking EGFR gene may
improve outcome for esophageal
cancer patients.

Mathematical method for
organized cancer gene
discoveries developed.

Bioinformatics method of cell
signaling increases understanding
of cancer and the signaling
malfunctions that help it grow
and spread.

The first formal statistical
translational clinical trial
methodology is developed.

Software created to make the
complex mathematical package
available to cancer centers
throughout the country.

Model developed to identify and
quantify cancer drug synergies.

Nurse-run smoking cessation
program started.

Chemical drug libraries purchased
to screen for compounds that kill
or inhibit tamoxifen-resistant
breast cancer cells.

Relationship between shortened
chromosome ends, called
telomeres, and increased
development of prostate
cancer in African-American
men is studied.

2007
The entire genetic blueprint
for colon and breast cancers is
deciphered.

HPV found to drive certain oral
cancers and multiple oral sex
partners determined most significant
risk factor. The research is
called one of the top cancer
advances of 2007 by the American
Society of Clinical Oncology.

Johns Hopkins team of CRF
investigators selected by National
Cancer Institute to map epigenetic
changes related to cancer.

Geriatric Oncology Program
established at Johns Hopkins
Bayview to improve clinical
research within the aging
population most commonly
affected by cancer.

Smokers in the Baltimore metro
area provide DNA samples to
help researchers pinpoint the
genetic changes that cause some
smokers to remain cancer free,
while 10-20 percent of smokers
develop lung cancer.

New data finds that an alteration
of the EGFR gene results
in poorer outcomes for patients
with esophageal cancer. Clinical
trials begin to test if adding
drugs that block EGFR expression
to standard chemotherapy
and radiation improves survival.

Investigators devise means to
sort out the accumulating genetic
data linked to cancer. They
develop a computerized, statistical
method to mathematically
decipher the significance of
specific genetic alterations.

An inpatient nurse-delivered
smoking cessation program tested
in 150 patients as pilot for a
standardized program in the
state’s acute-care hospitals.

A pilot study of a panel of six
genes is used to predict nonsmall
cell lung cancer behavior.

2008
A simple mouth rinse captures
genetic signature for head and
neck cancers and becomes prototype
for inexpensive screening
test for head and neck cancers.

A 3-D structure of the most
commonly mutated cancerpromoting
gene (oncogene)
PIK3CA is created, providing a
better understanding of how it is
altered in colon, lung, breast,
brain, stomach, and other
cancers. Researchers work to
develop mutation-specific
inhibitors as new
cancer therapies.

Pilot study is aimed
at improving clinical
trials patient accrual
by pinpointing specific
factors that mitigate
participation.

A study of Maryland communities
reveals environmental factors
that contribute to cancer
development.

Clinical trials begin of a new
drug and other combined
approaches to target and block
expression of Bcl-2, a gene
found to be over-expressed in
most small cell lung cancers and
linked to treatment resistance.

Patient navigators work with
low-income, uninsured women
in Baltimore City at high risk of
developing breast cancer to
facilitate education, screening,
and treatment.

Related Content

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.